NVO ▲ +0.4% - Novo Nordisk A/S $NVO Novo Nordisk: to Present 44 EASD Abstracts Sept. 28-Oct. 2 Across Wegovy, CagriSema and Next-Gen Amylin Pipeline ? • Novo will present new real-world data on Wegovy pill, including weight outcomes, treatment switching and patient-reported results. • CagriSema presentations will cover appetite regulation, food-cue brain responses, body composition and bone remodeling; zenagamtide Phase 2b data in type 2 diabetes will also be shown. • Additional data span Wegovy 7.2 mg, Ozempic 2.0 mg, cardio-renal outcomes and comparisons with tirzepatide. Novo Nordisk rose 0.4% on news it will present 44 abstracts at the European Association for the Study of Diabetes conference from September 28 to October 2, showcasing clinical data across its key weight-loss and diabetes programs including Wegovy, CagriSema, and pipeline candidates. The presentations will include real-world evidence on Wegovy's oral formulation, efficacy data for the dual GLP-1/GCG agonist CagriSema, and Phase 2b results for zenagamtide in type 2 diabetes. 16-SEP-2026 05:27 AM ET